1 / 17

Selling GlycoMark

Selling GlycoMark ? Elevator. ?Doctor ___, you may be aware that the UKPDS study showed every 1% decrease in hemoglobin A1c reduces risk of cardiovascular disease by 14%. . Selling GlycoMark - Elevator. ?It's obviously important to take advantage of HbA1c values so that you can help your patients. However, you may not be aware that HbA1c values can be misleading." .

zoey
Télécharger la présentation

Selling GlycoMark

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Selling GlycoMark

    2. Selling GlycoMark Elevator Doctor ___, you may be aware that the UKPDS study showed every 1% decrease in hemoglobin A1c reduces risk of cardiovascular disease by 14%.

    3. Selling GlycoMark - Elevator Its obviously important to take advantage of HbA1c values so that you can help your patients. However, you may not be aware that HbA1c values can be misleading.

    4. Selling GlycoMark - Elevator Unfortunately, some patients in the near normal HbA1c range actually are not in good glycemic control and remain at a high risk of multiple complications of diabetes.

    5. Selling GlycoMark If you have the physicians interest some or all of the following words and information may be useful:

    6. Selling GlycoMark My company ____________ has identified GlycoMark as the most significant new blood test for effective diabetes control and treatment. GlycoMark responds more rapidly than other diabetes markers to changes in hyperglycemia and can be used with hemoglobin A1c to determine what patients are, in fact, in glycemic control. Furthermore, GlycoMark has been found to be the most accurate test for drug efficacy

    7. Selling GlycoMark Many studies indicate that lowering HbA1c from 8.5 to below 6.5% can have a profound effect on lowering risks of cardiovascular disease, retinopathy, neuropathy and nephropathy and save lives.

    8. Selling GlycoMark Only GlycoMark, an assay of 1,5-anhydro-D-glucitol, can accurately tell you that your patients glycemia is, in fact, under control.

    9. Selling GlycoMark GlycoMark uniquely reflects all post-meal hyperglycemia over a 1 2 week time frame. Hemoglobin A1c and fructosamine average hypo- and hyperglycemia over 2 3 months and 2 3 weeks, respectively.

    10. Selling GlycoMark Due to this averaging, HbA1c values in the supposed near normal ranges, 6.5 to 8.5%, may actually have abnormally high and frequent post-meal glycemic excursions. Studies indicate that a significant number of your patients in this near normal HbA1c range are actually not in glycemic control.

    11. Selling GlycoMark A recent study showed that two patients undergoing CGMS had similar near normal hemoglobin A1c levels (approximately 7.4%); however, one of these individuals had frequent and high post meal blood glucose spikes. GlycoMark was able to differentiate these patients.* * Dungan K. et al. 2006. 1,5-anhydoglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care; 29;6: 1214 1219. CGMS is continuous glucose monitoring system

    12. Selling GlycoMark Pharmaceutical companies use GlycoMark to show the efficacy of their anti-hyperglycemic drugs such as sitagliptin, exenatide and pramlintide. Only GlycoMark reflects significant improvement in post meal hyperglycemia in all of these clinical trials and may also be useful in regulating dosage.

    13. Selling GlycoMark GlycoMark is FDA approved and is now in the IDF guidelines for diabetes care.

    14. Selling GlycoMark GlycoMark is the most effective way to manage both post-meal hyperglycemia and anti-hyperglycemic drug therapy.

    15. Selling GlycoMark GlycoMark is easy to use, requires a single standard blood draw that can be taken at any time. It is reimbursable by Medicare and most private insurers.

    16. Changing Behavior Promote GlycoMark as an adjunct test to HbA1c in order to effectively lower risks of cardiovascular, retinopathy, neuropathy, nephropathy, etc. . GlycoMark should be promoted as an adjunct to hemoglobin A1c for monitoring post meal hyperglycemia in moderately controlled patients. Once hemoglobin A1c has identified patients in the near normal range of 6.5 to 8.5%, GlycoMark is used to differentiate patients who are in true compliance. Only GlycoMark can effectively reflect anti-hyperglycemic drug efficacy. GlycoMark can also be promoted as a better test than either hemoglobin A1c or fructosamine because it uniquely reflects hyperglycemia over 1 2 weeks. Endocrinologists will grasp this quickly. Try to focus on PPG control and lowering risks when presenting GlycoMark to primary care physicians.

    17. Changing Behavior Try to get the doctor to test some of his patients (recommend a ten patients study) using HbA1c and GlycoMark to differentiate patients who are not in control. He should find that at least 25% of these patients will not be in proper control. GlycoMark can be tested using either serum (red top or gel barrier) or EDTA plasma (lavender top). One ml of sample is recommended.

    18. GlycoMark Seldom are tests introduced with such significant benefits for patients, physicians, the healthcare system. You will find the recognition of GlycoMark among physicians, especially endocrinologists, is already high. This should facilitate your sales and provide an entry to new accounts. Follow-up is essential to see how they are using GlycoMark to help their diabetic patients better manage their disease.

More Related